From the Massachusetts General Hospital and Harvard Medical School, Boston, MA (D.M.S.); Duke Clinical Research Institute, Durham, NC (X.H., S.M.O., E.P.); University of Colorado School of Medicine-Anschutz Medical Campus, Aurora, CO, and Denver Department of Veterans Affairs Medical Center, Denver, CO (F.L.G.); All Children's Hospital, John Hopkins University, Saint Petersburg, FL (J.P.J.); University of Florida College of Medicine, Jacksonville, FL (F.H.E.); Children's Hospital of Illinois and the University of Illinois College of Medicine, Peoria, IL (K.F.W.); Yale-New Haven Health Services Corporation Center for Outcomes Research and Evaluation (CORE) and Yale School of Medicine, New Haven, CT (L.G.S., E.D.); Society of Thoracic Surgeons, Chicago, IL (C.M.S.); and Centers for Medicare and Medicaid Services, Baltimore, MD (L.H.).
Circulation. 2014 Jul 29;130(5):399-409. doi: 10.1161/CIRCULATIONAHA.113.007541. Epub 2014 Jun 10.
Reducing readmissions is a major healthcare reform goal, and reimbursement penalties are imposed for higher-than-expected readmission rates. Most readmission risk models and performance measures are based on administrative rather than clinical data.
We examined rates and predictors of 30-day all-cause readmission following coronary artery bypass grafting surgery by using nationally representative clinical data (2008-2010) from the Society of Thoracic Surgeons National Database linked to Medicare claims records. Among 265 434 eligible Medicare records, 226 960 (86%) were successfully linked to Society of Thoracic Surgeons records; 162 572 (61%) isolated coronary artery bypass grafting admissions constituted the study cohort. Logistic regression was used to identify readmission risk factors; hierarchical regression models were then estimated. Risk-standardized readmission rates ranged from 12.6% to 23.6% (median, 16.8%) among 846 US hospitals with ≥30 eligible cases and ≥90% of eligible Centers for Medicare and Medicaid Services records linked to the Society of Thoracic Surgeons database. Readmission predictors (odds ratios [95% confidence interval]) included dialysis (2.02 [1.87-2.19]), severe chronic lung disease (1.58 [1.49-1.68]), creatinine (2.5 versus 1.0 or lower:1.49 [1.41-1.57]; 2.0 versus 1.0 or lower: 1.37 [1.32-1.43]), insulin-dependent diabetes mellitus (1.45 [1.39-1.51]), obesity in women (body surface area 2.2 versus 1.8: 1.44 [1.35-1.53]), female sex (1.38 [1.33-1.43]), immunosuppression (1.38 [1.28-1.49]), preoperative atrial fibrillation (1.36 [1.30-1.42]), age per 10-year increase (1.36 [1.33-1.39]), recent myocardial infarction (1.24 [1.08-1.42]), and low body surface area in men (1.22 [1.14-1.30]). C-statistic was 0.648. Fifty-two hospitals (6.1%) had readmission rates statistically better or worse than expected.
A coronary artery bypass grafting surgery readmission measure suitable for public reporting was developed by using the national Society of Thoracic Surgeons clinical data linked to Medicare readmission claims.
降低再入院率是医疗改革的主要目标之一,对于再入院率高于预期的情况,医疗机构会受到罚款处罚。大多数再入院风险模型和绩效指标都是基于行政数据,而非临床数据。
我们使用全国范围内具有代表性的临床数据(2008-2010 年),从美国胸外科医师学会国家数据库中提取数据,并与医疗保险索赔记录进行关联,对冠状动脉旁路移植术后 30 天内全因再入院率及其预测因素进行了研究。在 265434 份符合条件的医疗保险记录中,226960 份(86%)成功与美国胸外科医师学会记录相关联;162572 份(61%)单纯冠状动脉旁路移植术入院患者构成了研究队列。我们采用逻辑回归模型确定再入院风险因素;然后,采用分层回归模型进行估计。在 846 家至少有 30 例符合条件的患者和至少 90%符合医疗保险和医疗补助服务中心记录与美国胸外科医师学会数据库相关联的医院中,风险标准化再入院率范围为 12.6%至 23.6%(中位数为 16.8%)。再入院预测因素(比值比[95%置信区间])包括透析(2.02[1.87-2.19])、严重慢性肺部疾病(1.58[1.49-1.68])、肌酐(2.5 与 1.0 或更低:1.49[1.41-1.57];2.0 与 1.0 或更低:1.37[1.32-1.43])、胰岛素依赖型糖尿病(1.45[1.39-1.51])、女性肥胖(体表面积 2.2 与 1.8:1.44[1.35-1.53])、女性(1.38[1.33-1.43])、免疫抑制(1.38[1.28-1.49])、术前心房颤动(1.36[1.30-1.42])、年龄每增加 10 岁(1.36[1.33-1.39])、近期心肌梗死(1.24[1.08-1.42])和男性低体表面积(1.22[1.14-1.30])。C 统计量为 0.648。52 家医院(6.1%)的再入院率明显好于或差于预期。
通过使用美国胸外科医师学会全国临床数据,并与医疗保险再入院索赔记录进行关联,开发了一种适合公共报告的冠状动脉旁路移植术再入院评估指标。